These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8791 related articles for article (PubMed ID: 17492842)

  • 1. An update on malignant melanoma vaccine research: insights into mechanisms for improving the design and potency of melanoma therapeutic vaccines.
    Ralph SJ
    Am J Clin Dermatol; 2007; 8(3):123-41. PubMed ID: 17492842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines and melanoma.
    Ott PA; Fritsch EF; Wu CJ; Dranoff G
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):559-69. PubMed ID: 24880947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Are immunological treatments beneficial for malignant melanoma of the skin?].
    Vihinen P; Vuoristo MS; Hernberg M; Pyrhönen S
    Duodecim; 2010; 126(14):1701-10. PubMed ID: 20804089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on active specific immunotherapy with melanoma vaccines.
    Conforti AM; Ollila DW; Kelley MC; Gammon G; Morton DL
    J Surg Oncol; 1997 Sep; 66(1):55-64. PubMed ID: 9290695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next generation of immunotherapy for melanoma.
    Kirkwood JM; Tarhini AA; Panelli MC; Moschos SJ; Zarour HM; Butterfield LH; Gogas HJ
    J Clin Oncol; 2008 Jul; 26(20):3445-55. PubMed ID: 18612161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium.
    Curigliano G; Criscitiello C; Esposito A; Fumagalli L; Gelao L; Locatelli M; Minchella I; Goldhirsch A
    Breast; 2013 Aug; 22 Suppl 2():S96-9. PubMed ID: 24074802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Vaccine strategies against melanoma].
    Ghiringhelli F; Zitvogel L
    Med Sci (Paris); 2006 Feb; 22(2):183-7. PubMed ID: 16457760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of melanoma vaccines: active specific immunotherapy for melanoma patients.
    Ollila DW; Kelley MC; Gammon G; Morton DL
    Semin Surg Oncol; 1998 Jun; 14(4):328-36. PubMed ID: 9588726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor vaccines: a role in preventing recurrence in melanoma?
    Sabel MS; Sondak VK
    Am J Clin Dermatol; 2002; 3(9):609-16. PubMed ID: 12444803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
    Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
    Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of melanoma vaccines.
    Kuhn CA; Hanke CW
    Dermatol Surg; 1997 Aug; 23(8):649-54; discussion 654-5. PubMed ID: 9256911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active immunotherapy with allogeneic tumor cell vaccines: present status.
    Chan AD; Morton DL
    Semin Oncol; 1998 Dec; 25(6):611-22. PubMed ID: 9865676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.
    Weber JS; Hamid O; Chasalow SD; Wu DY; Parker SM; Galbraith S; Gnjatic S; Berman D
    J Immunother; 2012 Jan; 35(1):89-97. PubMed ID: 22130166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
    BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
    Berinstein NL
    Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanoma antigens and targets for vaccination.
    Kang N; Truman H; Sanders R; Kupsch J
    Br J Hosp Med; 1997 Sep 17-30; 58(6):282-6. PubMed ID: 9488805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Melanoma immunotherapy: dendritic cell vaccines].
    Lozada-Requena I; Núñez C; Aguilar JL
    Rev Peru Med Exp Salud Publica; 2015; 32(3):555-64. PubMed ID: 26580940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.
    Yan J; Tingey C; Lyde R; Gorham TC; Choo DK; Muthumani A; Myles D; Weiner LP; Kraynyak KA; Reuschel EL; Finkel TH; Kim JJ; Sardesai NY; Ugen KE; Muthumani K; Weiner DB
    Cancer Gene Ther; 2014 Dec; 21(12):507-17. PubMed ID: 25394503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 440.